Gliomas News and Research

RSS

Cell phones and cancer – link established

In its latest announcement the World Health Organization (WHO) said that radiation from cell phones can possibly cause cancer. According to the WHO's International Agency for Research on Cancer (IARC), radiofrequency electromagnetic fields have been classified as possibly carcinogenic to humans (group 2B) on the basis of an increased risk for glioma that some studies have associated with the use of wireless phones.

1 Jun 2011

Global scientists rebuke coming decision on carcinogenicity of radiofrequency and microwaves

In collaboration with the International EMF Alliance (IEMFA), scientists from Europe, North America, Australia and Israel have sent an Open Letter to Dr. Christopher Wild, Director of the International Agency for Research on Cancer (IARC), calling for a postponement of the forthcoming meeting May 24-31, 2011 in Lyon, France, “Non-Ionizing Radiation, Part II: Radiofrequency Electromagnetic Field [includes mobile telephones],” at which determination of the carcinogenicity of cell phones and wireless technologies will be made.

22 May 2011

Rally Foundation distributes $700,000 nationwide to support childhood cancer research

Rally Foundation, a national non-profit organization committed to research to fight childhood cancer, has announced its annual funding allocation for 2011 and has selected 15 hospitals across the country to receive more than $700,000.

19 May 2011

Two genes linked to worst cases of esophageal cancer

University of Rochester Medical Center researchers have pinpointed two genes that are amplified in the worst cases of esophageal cancer, providing data to support a new investigational treatment that targets those same genes.

19 May 2011

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.

12 May 2011

Seventh Annual Neuro-Oncology Symposium to be held at Hackensack University Medical Center

The John Theurer Cancer Center at Hackensack University Medical Center will host the Seventh Annual Neuro-Oncology Symposium on Friday, May 20 from 7:30am - 1:00pm. This continuing medical education conference will present the latest neuro-oncology trends by leaders in the field.

10 May 2011

Research experts to speak at brain tumor educational conference

Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.

5 May 2011

Nutlin-3a molecules stimulate signal to induce cell death and senescence in brain cancer

Researchers of Apoptosis and Cancer Group of the Bellvitge Biomedical Research Institute (IDIBELL) have found that a small molecule, Nutlin-3a, an antagonist of MDM2 protein, stimulates the signalling pathway of another protein, p53.

21 Apr 2011

Minimizing neurological side effects in high-grade glioma patients may improve survival

Minimizing neurological side effects in patients with high-grade glioma from chemoradiation may result in improved patient survival, a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests. These findings were reported in the April issue of the British Journal of Cancer.

20 Apr 2011

Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma

A novel brain tumor vaccine clinical trial study demonstrates a longer survival time in patients with glioblastoma, according to findings being presented at the 79th Annual Scientific Meeting of the American Association of Neurological Surgeons in Denver.

12 Apr 2011

Hypericin may treat recurrent malignant brain tumors

Researchers have found that a synthetic version of hypericin, a compound naturally found in St. John's wort, may be a promising treatment for patients with recurrent malignant brain tumors. Their findings were published online on March 31, 2011 in the journal Cancer.

12 Apr 2011

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris Group announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.

8 Apr 2011

Study: Stem cells may open door to new tools for colorectal cancer detection, treatment

Colorectal cancer cells trigger a set of genes similar to those found in intestinal stem cells, scientists at the Institute for Research in Biomedicine have found.

18 Mar 2011

Researchers develop novel system to show how specific mutations can induce glioblastoma

Mutations in three pathways important for suppressing tumors cooperate to launch glioblastoma, an aggressive brain tumor that strikes children and adults. But new research from St. Jude Children's Research Hospital scientists shows those changes alone are not sufficient to cause cancer.

15 Mar 2011

New discovery in glioma-associated metabolic changes

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome", in The Proceedings of the National Academy of Sciences.

3 Mar 2011

No robust conclusions possible on advantages or disadvantages of PET

Malignant gliomas are fast-growing brain tumours with poor prospects of recovery depending on disease stage. Experts hope that the examination of patients by means of positron emission tomography (PET) is more helpful in the choice of the right treatment than other procedures. In a final report the German Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated the benefit of PET in the detection of recurrences. According to this report, no robust conclusions are possible on the advantages or disadvantages of PET.

20 Jan 2011

Study supports use of telomerase inhibitors for treatment of childhood cancers

Geron Corporation today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, selectively targets cancer stem cells in pediatric tumors of neural origin.

11 Jan 2011

Scientists identify type of cell at the origin of brain tumors

Scientists have identified the type of cell that is at the origin of brain tumors known as oligodendrogliomas, which are a type of glioma - a category that defines the most common type of malignant brain tumor.

7 Jan 2011

Photon-based radiation therapy may result in better survival rate in patients with spinal-cord tumor

A study comparing the long-term outcomes of patients with spinal-cord tumors following radiation therapy suggests that certain subsets of patients have better long-term survival.

23 Dec 2010

Study broadens understanding of role of IDH1 and IDH2 mutations in AML

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced the publication of a paper in Cancer Cell that illuminates the mechanism by which 2-hydroxyglutarate (2HG), and the mutations in the metabolic genes IDH1 and IDH2 that produce it, may be driving the growth of tumors in patients with acute myeloid leukemia (AML).

15 Dec 2010